What Changed in the 2026 FDA Peptide Decision?

No, the FDA did not approve BPC-157, TB-500, KPV or the other peptides women ask about for skin, recovery and body shape in 2026. Effective April 23, twelve peptides left the agency's highest concern list, and on July 23 and 24 an advisory panel recommended six of them for future compounding. Those recommendations do not allow bulk compounding yet because the FDA has not completed the formal process to add them to the compounding list.

What did the FDA remove in April?

Category 2 is the FDA short list for bulk substances that raise significant safety concerns. Effective April 23, 2026, the FDA removed twelve peptides from that list, including BPC-157, KPV and TB-500, after the original nominations were withdrawn (Amanecia Health summary).

Removal took those peptides out of the highest concern group. They remained outside the 503A Bulks List, the list of bulk ingredients licensed pharmacies may use to prepare a prescription when no approved product exists, and they waited for a separate review (FDA bulk substances guide).

What did the July panel recommend, even against staff advice?

The Pharmacy Compounding Advisory Committee advises the FDA on which bulk ingredients belong on the 503A list. FDA scientists asked the panel to reject all seven peptides under review because the clinical data were limited and the drug descriptions were incomplete (Mintz review of FDA briefing papers). The panel voted the other way for six.

On July 23, BPC-157, KPV and TB-500 each received 8 yes votes, 6 no votes and 1 abstention, and MOTS-c received 7 yes votes, 5 no votes and 2 abstentions (AJMC vote report). Semax and Epitalon also received favorable votes on July 24, while emideltide, also called DSIP, failed with 6 yes votes and 7 no votes (Clinical Peptide hearing analysis). The FDA had asked the panel to weigh BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, and MOTS-c for obesity and osteoporosis (FDA meeting page).

Can pharmacies make these peptides now?

Pharmacies cannot prepare these peptides in bulk under 503A yet. Advisory votes leave the law unchanged. The FDA must decide whether to start formal rulemaking to add each substance to the 503A list, a process that often takes six to twelve months (NCPA meeting summary) (Peptide Dossier process guide).

Until the FDA issues a final rule, the peptides stay in the same legal position they held after April, out of Category 2 but outside the compounding list. You can watch the July discussion and read the briefing papers on the FDA advisory calendar while you wait for that decision.